Metropolis Healthcare (METROPOLIS): Filings Show Margin Expansion and a Stated Mix Target
Metropolis Healthcare (NSE: METROPOLIS, BSE: 542650) reported Q1FY27 results on August 4, 2026, showing consolidated revenue of ₹4,502.15 million, up 16.6% year-on-year, with EBITDA margin expanding to 25.8%. PAT attributable to owners rose 25.8% YoY to ₹566.67 million, per the company's BSE filing.
Revenue grew 16.6% in Q1FY27
The Q1FY27 results filing (August 4, 2026) showed revenue of ₹450.22 crore, up 16.6% YoY and 6.0% QoQ. EBITDA was ₹116.3 crore. The filing attributed the operating margin to "volume-led growth and richer mix" after two consecutive quarters of expansion.
What management said on the Q1FY27 concall
On the earnings call held August 10, 2026, management reported broad-based 17% revenue growth and 210 bps margin expansion. Guidance for FY27 was maintained: 14-15% revenue growth and 100-150 bps margin improvement, driven by volume and specialty mix.
Specialty mix is the disclosed lever
A narrative in the filings describes Specialty testing at 40% of revenue and TruHealth wellness at 18%, both growing faster than the company average. Management stated: "we aim to increase contribution ... to 45% from the current 40%." This is a stated target, not a forecast.
Three-year targets in the August 27 presentation
An investor presentation filed August 27, 2026 stated targets of mid-teen revenue growth and 27–28% EBITDA margin over three years, along with expansion to 1,000 own centres.
Core acquisition integration status
Filings describe the Core acquisition as now in "final integration," transitioning from integration to growth. North India share is 18%, described as the fastest-growing region. Management characterized the acquisition as "proven to be the right decision."
A corporate simplification move
On August 27, 2026, the company transferred its External Quality Assessment Services Business Division (EQAS) to its wholly owned subsidiary, Metropolis Quality Solutions Private Limited, via slump sale for ₹1.25 crore, discharged by issuance of equity shares of the subsidiary.
What to watch, per the filings
The stated items ahead: the 45% Specialty revenue mix target, FY27 guidance of 14-15% revenue growth and 100-150 bps margin improvement, and the three-year margin target of 27-28%. These are the company's own disclosed numbers.
The filing evidence
| Date | What the filing said | Detail | Source |
|---|---|---|---|
| Specialty revenue share target — 45% | [Metropolis] aims to increase contribution of [Specialty Diagnostics] portfolio to 45% from the current 40%. | ||
| 4 Aug 2026 | Metropolis Healthcare Q1FY27: Revenue ₹450 Cr (+16.6% YoY), PAT ₹56.7 Cr (+25.8% YoY), EBITDA margin expands to 25.8% (+110bps YoY) driven by volume and mix improvement; margin sequential dip of 160bps from Q4FY27's 27.4%. | filing | |
| 4 Aug 2026 | Q1FY27 revenue was ₹450.22 crore, up 16.6% YoY, while EBITDA was ₹116.3 crore and PAT ₹56.67 crore; volume-led growth and richer mix lifted operating margin after two consecutive quarters of expansion. | filing | |
| 4 Aug 2026 | Q1FY27 consolidated revenue rose to ₹4,502.15 million (+16.6% YoY, +6.0% QoQ) while EBITDA margin expanded to 25.8%, extending the margin recovery and driving PAT attributable to owners up 25.8% YoY to ₹566.67 million. | filing | |
| 10 Aug 2026 | Q1FY27 sees broad-based 17% revenue growth and 210 bps margin expansion; management maintains FY27 guidance of 14-15% revenue growth and 100-150 bps margin improvement, driven by volume and specialty mix. | filing | |
| 27 Aug 2026 | Metropolis Healthcare targets mid-teen revenue growth, 27–28% EBITDA margin over three years, and expansion to 1,000 own centres. | filing | |
| 5 Jul 2026 | Metropolis Healthcare reports ~16% YoY revenue growth in Q1FY27, driven by patient volumes and product mix improvement | Metropolis Healthcare issued a business update for Q1FY27 (quarter ended June 30, 2026), highlighting consolidated revenue growth of approximately 16% year-on-year, with TruHealth Wellness and Specialty segments as the fastest growing, B2C and B2B volume growth, and EBITDA margins improving YoY while remaining stable QoQ. | filing |
| 27 Aug 2026 | Metropolis Healthcare completes transfer of its External Quality Assessment Services Business Division to subsidiary Metropolis Quality Solutions Private Limited via slump sale for INR 1.25 crore. | The company transferred its EQAS Division to its wholly owned subsidiary, Metropolis Quality Solutions Private Limited, as a going concern on a slump sale basis for a consideration of INR 1.25 crore, discharged by issuance of equity shares of the subsidiary. The transfer is effective August 27, 2026. | filing |
Quick answers
- What did Metropolis Healthcare disclose?
- Metropolis Healthcare (NSE: METROPOLIS, BSE: 542650) reported Q1FY27 results on August 4, 2026, showing consolidated revenue of ₹4,502.15 million, up 16.6% year-on-year, with EBITDA margin expanding to 25.8%. PAT attributable to owners rose 25.8% YoY to ₹566.67 million, per the company's BSE filing.
- What are the key numbers?
- The Q1FY27 results filing (August 4, 2026) showed revenue of ₹450.22 crore, up 16.6% YoY and 6.0% QoQ. EBITDA was ₹116.3 crore. The filing attributed the operating margin to "volume-led growth and richer mix" after two consecutive quarters of expansion.
- What does Metropolis Healthcare say comes next?
- The stated items ahead: the 45% Specialty revenue mix target, FY27 guidance of 14-15% revenue growth and 100-150 bps margin improvement, and the three-year margin target of 27-28%. These are the company's own disclosed numbers.
Research and educational content only. Not investment advice. Drafted from regulatory filings and published automatically — see our editorial policy.